A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 212
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PS
Long Form : phosphorothioate
No. Year Title Co-occurring Abbreviation
2018 5'-Phosphorothiolate Dinucleotide Cap Analogues: Reagents for Messenger RNA Modification and Potent Small-Molecular Inhibitors of Decapping Enzymes. 5'-PSL, gamma-PSL, m7G, mRNA
2018 A signal-on, colorimetric determination of deoxyribonuclease I activity utilizing the photoinduced synthesis of gold nanoparticles. DNase I, Thr
2018 Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. 2'-MOE, ASOs, cET, DBHS
2018 Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. ASOs, EGFR
2018 Chromatographic approaches for the characterization and quality control of therapeutic oligonucleotide impurities. ---
2018 Detection of phosphorothioated (PS) oligonucleotides in horse plasma using a product ion (m/z 94.9362) derived from the PS moiety for doping control. PSOs
2018 Electrochemical Biosensor Using DNA Embedded Phosphorothioate Modified RNA for Mercury Ion Determination. ---
2018 Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation. ASOs
2018 Instantaneous Iodine-assisted DNAzyme Cleavage of Phosphorothioate RNA. ---
10  2018 Optimizing Molecular Beacons for Intracellular Analysis of RNA. 2Me, MBs
11  2018 Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity. PO
12  2018 Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver. ASOs
13  2018 Solid-Phase Synthesis of Phosphorothioate Oligonucleotides Using Sulfurization Byproducts for in Situ Capping. ---
14  2018 Structural Determinants for the Interactions of Chemically Modified Nucleic Acids with the Stabilin-2 Clearance Receptor. ASOs
15  2018 Structural insight into antisense gapmer-RNA oligomer duplexes through molecular dynamics simulations. LNA, MD, MOE, SASA
16  2017 An Exceptionally Selective DNA Cooperatively Binding Two Ca2+ Ions. ---
17  2017 Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia. GPVI, LNA, ON, PF4
18  2017 Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice. ODNs
19  2017 Cellular uptake and trafficking of antisense oligonucleotides. ASOs
20  2017 Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver. ASOs, EON, NPCs
21  2017 Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. ASO
22  2017 Electronic Structures of LNA Phosphorothioate Oligonucleotides. LNA, QM
23  2017 Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. ASOs, HSA, PO
24  2017 Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on In Vitro Cytotoxicity. ds, DSBs, ONs, ss
25  2017 Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. ASOs, EEs, ILVs, LBPA, LEs
26  2017 Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping InVitro. AO
27  2017 Reconstruction of Toll-like receptor 9-mediated responses in HEK-Blue hTLR9 cells by transfection of human macrophage scavenger receptor 1 gene. hMSR1, hTLR9, PO, SEAP, ssCpG
28  2017 Two Completely Different Mechanisms for Highly Specific Na+ Recognition by DNAzymes. ---
29  2016 A primerless molecular diagnostic: phosphorothioated-terminal hairpin formation and self-priming extension (PS-THSP). PS-THSP
30  2016 An Ultrasensitive Light-up Cu(2+) Biosensor Using a New DNAzyme Cleaving a Phosphorothioate-Modified Substrate. ---
31  2016 Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. ANXA2, ASOs, EEs, LEs
32  2016 Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells. 2'-OMe, GISTs
33  2016 Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and d-altritol nucleic acid-modified 2'-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro. 2'-OMe, ANA, AO, CeNA, DMD, HNA
34  2016 Hg(2+) detection using a phosphorothioate RNA probe adsorbed on graphene oxide and a comparison with thymine-rich DNA. NGO
35  2016 Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity. ASOs, LNA, MOE
36  2016 In Vitro Selection of a DNAzyme Cooperatively Binding Two Lanthanide Ions for RNA Cleavage. ---
37  2016 In vivo knockdown of basal forebrain p75 neurotrophin receptor stimulates choline acetyltransferase activity in the mature hippocampus. AS, ChAT, MO
38  2016 Noninvasive visualization of microRNA-155 in multiple kinds of tumors using a radiolabeled anti-miRNA oligonucleotide. 2'-OMe, AMO-155, HPLC
39  2016 Single-molecule detection and tracking of RNA transcripts in living cells using phosphorothioate-optimized 2'-O-methyl RNA molecular beacons. 2Me, MBs
40  2016 Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. ASOs
41  2016 Synergistic effect of phosphorothioate, 5'-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. ---
42  2015 Biochemical Characterization of a Lanthanide-Dependent DNAzyme with Normal and Phosphorothioate-Modified Substrates. ---
43  2015 Cleavable Molecular Beacon for Hg(2+) Detection Based on Phosphorothioate RNA Modifications. ---
44  2015 Desulfurization Activated Phosphorothioate DNAzyme for the Detection of Thallium. Tl
45  2015 In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. ASOs, MM, OTEs
46  2015 Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. anti, GPVI
47  2015 Phosphorothioate DNA Stabilized Fluorescent Gold and Silver Nanoclusters. NCs
48  2015 Phosphorothioate modification of chimeric 2-O-methyl RNA/ethylene-bridged nucleic acid oligonucleotides increases dystrophin exon 45 skipping capability and reduces cytotoxicity. AO, DMD, ENA
49  2015 Synthesis of a stabilized 177Lu-siRNA complex and evaluation of its stability and RNAi activity. 2'-OMe, siRNA
50  2014 Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. 2'-OMe, SSOs
51  2014 Exploring directional invasion of serum nuclease into siRNA duplexes by asymmetrical terminal modifications. ---
52  2014 Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides. BNA, DDSs, PCSK9, PET, PO
53  2014 Sensing parts-per-trillion Cd(2+), Hg(2+), and Pb(2+) collectively and individually using phosphorothioate DNAzymes. ---
54  2014 Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. ASOs
55  2014 Tandem phosphorothioate modifications for DNA adsorption strength and polarity control on gold nanoparticles. ---
56  2014 TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. ASOs, Ran, TCP-1
57  2013 Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. AONs, ONs, siRNAs
58  2013 Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. 2'OmePS, AO, DMD, MOE
59  2013 Electron transfer followed by collision-induced dissociation (NET-CID) for generating sequence information from backbone-modified oligonucleotide anions. CID, MBOs, PO
60  2013 Enzymatic cleavage of type II restriction endonucleases on the 2'-O-methyl nucleotide and phosphorothioate substituted DNA. 2'-OMeN
61  2013 Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. 2'OMe, AMOs, LNA, miRNA
62  2013 SNP detection in mRNA in living cells using allele specific FRET probes. FRET, SNP
63  2012 Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo. apoB, BNA, IFN-alpha, isRNA, LNA, RNAi, siRNAs, TC
64  2012 DNA binding to proteolytically activated TLR9 is sequence-independent and enhanced by DNA curvature. TLR9
65  2012 Efficient stabilization of phosphodiester (PO), phosphorothioate (PS), and 2'-O-methoxy (2'-OMe) DNARNA hybrid duplexes by amino sugars. 2'-OMe, PO
66  2012 Gene silencing activity of siRNA molecules containing phosphorodithioate substitutions. siRNAs
67  2012 Nitroxide sensing of a DNA microenvironment: mechanistic insights from EPR spectroscopy and molecular dynamics simulations. EPR, MD
68  2012 TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. ASOs, cET, MOE, tcDNA
69  2011 Cell stress is related to re-localization of Argonaute 2 and to decreased RNA interference in human cells. CHX, hAgo2, ON, PBs, RISC, RNAi, SGs
70  2011 Conformational variability of organophosphorus hydrolase upon soman and paraoxon binding. MD, OPH, P-F, PO
71  2011 New vistas on TLR9 activation. IN-ODNs, ODNs, PD, TLR9ecto
72  2011 Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. HEK, INH-ODN, PO, TLR
73  2011 Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. LNA, miR-122, OMe, ONs, PNA, PO
74  2011 The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes. ODN, PO, TLR9
75  2011 Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. ASOs, i.t, LNA, siRNA
76  2010 beta-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression. ASOs
77  2010 Efficient delivery of intact phosphodiester oligonucleotides by poly-beta-amino esters. FRET, PO-ODNs, siRNA
78  2010 Phosphothioate oligodeoxynucleotides inhibit Plasmodium sporozoite gliding motility. ODNs, TLR9
79  2010 Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides. ODNs, PO, Y-DNA
80  2009 A convenient thiazole orange fluorescence assay for the evaluation of DNA duplex hybridization stability. mRNA, PO, TO
81  2009 Evaluation of antisense oligonucleotide loaded chitosan nanoparticles; characterization and antisense effect. ASODN, NPs, PO, TPP
82  2009 Optical antisense tumor targeting in vivo with an improved fluorescent DNA duplex probe. cDNA, PO
83  2009 Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery. ON, siRNA
84  2009 The identity of the nucleophile substitution may influence metal interactions with the cleavage site of the minimal hammerhead ribozyme. mHHRz
85  2008 Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. PO
86  2008 In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. PO
87  2008 Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies. Ago2, RER, RNAi, siRNA
88  2008 Significance of stereochemistry of 3'-terminal phosphorothioate-modified primer in DNA polymerase-mediated chain extension. dNTPs, SBE
89  2008 The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. PD, TLR9
90  2008 The sweetness of the DNA backbone drives Toll-like receptor 9. PD, TLR9
91  2007 A polysaccharide carrier to effectively deliver native phosphodiester CpG DNA to antigen-presenting cells. PO, TLR9
92  2007 Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. cGVHD
93  2007 Cell culture and xenograft-bearing animal studies of radiolabeled antisense DNA carrier nanoparticles with streptavidin as a linker. PO
94  2007 Comparison of several linear fluorophore- and quencher-conjugated oligomer duplexes for stability, fluorescence quenching, and kinetics in vitro and in vivo in mice. PO
95  2007 Optical antisense imaging of tumor with fluorescent DNA duplexes. cDNA, PO
96  2006 Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. 2'-OMe, DMED, LNAs
97  2006 CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. DC, ODN, PD, ss, TLR9
98  2006 Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Ig, IL, PBMC, PO
99  2006 Role of scavenger receptor MARCO in macrophage responses to CpG oligodeoxynucleotides. CpG-ODN
100  2006 Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. 2'-OMe, RISC, RNAi, siRNAs